Skip to main content
. 2019 Mar 11;26(1):262–272. doi: 10.1080/10717544.2019.1580797

Figure 1.

Figure 1.

Schematic illustration of HA-TPD-CL-PTX/SOR liposome for co-delivery of PTX and SOR to overcome MDR in cancer cells. Drug delivery includes steps of intravenous injection, active targeting of liposome, degradation of HA by HAase together with the exposure of PLL-DA at HAase-rich lysosome, release of drugs, action on mitochondria function and inhibition of P-gp efflux by TPGS to further enhance drug accumulation in cancer cells.